MAIA
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.14 | $0 | -$5M |
| 2025 Q4 | -0.09 | $0 | -$7M |
| 2025 Q3 | -0.27 | $0 | -$3M |
| 2025 Q2 | -0.18 | $0 | -$4M |
| 2025 Q1 | -0.16 | $0 | -$4M |
| 2024 Q4 | -0.14 | $0 | -$4M |
| 2024 Q3 | -0.11 | $0 | -$4M |
| 2024 Q2 | -0.40 | $0 | -$5M |